The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Feb. 02, 2021
Filed:
Dec. 13, 2016
Applicant:
Sarissa Inc., London, CA;
Inventors:
Mark D. Vincent, London, CA;
Peter Ferguson, London, CA;
D. James Koropatnick, London, CA;
Mateusz Rytelewski, Mississauga, CA;
Assignee:
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C12N 15/113 (2010.01); A61K 31/713 (2006.01); A61K 33/243 (2019.01); A61K 45/06 (2006.01); A61K 31/502 (2006.01); A61K 31/712 (2006.01); A61K 31/7125 (2006.01);
U.S. Cl.
CPC ...
C12N 15/1135 (2013.01); A61K 31/502 (2013.01); A61K 31/712 (2013.01); A61K 31/713 (2013.01); A61K 31/7125 (2013.01); A61K 33/243 (2019.01); A61K 45/06 (2013.01); C12N 15/113 (2013.01); C12N 15/1137 (2013.01); C12Y 201/01045 (2013.01); C12N 2310/11 (2013.01); C12N 2310/14 (2013.01); C12N 2310/315 (2013.01); C12N 2310/321 (2013.01); C12N 2310/341 (2013.01); C12N 2310/346 (2013.01); C12N 2320/31 (2013.01);
Abstract
Methods of treating cancer using antisense based therapies including antisense oligonucleotides of si RNAs directed against DNA double-strand break repair proteins such as BRCA2 or RAD51 are provided. The antisense based therapies can be used alone, in tandem or in combination with other cancer therapies, in particular with therapies that lead to DNA damage, inhibition of DNA repair or inhibition of DNA synthesis, such as radiation, platinum drugs, alkylating agents, PARP inhibitors, or inhibitors of thymidylate synthase.